Article

Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy

Department of Neurology, Philipps-Universität, Marburg, Germany.
Nature Genetics (Impact Factor: 29.65). 07/2011; 43(7):699-705. DOI: 10.1038/ng.859
Source: PubMed

ABSTRACT Progressive supranuclear palsy (PSP) is a movement disorder with prominent tau neuropathology. Brain diseases with abnormal tau deposits are called tauopathies, the most common of which is Alzheimer's disease. Environmental causes of tauopathies include repetitive head trauma associated with some sports. To identify common genetic variation contributing to risk for tauopathies, we carried out a genome-wide association study of 1,114 individuals with PSP (cases) and 3,247 controls (stage 1) followed by a second stage in which we genotyped 1,051 cases and 3,560 controls for the stage 1 SNPs that yielded P ≤ 10(-3). We found significant previously unidentified signals (P < 5 × 10(-8)) associated with PSP risk at STX6, EIF2AK3 and MOBP. We confirmed two independent variants in MAPT affecting risk for PSP, one of which influences MAPT brain expression. The genes implicated encode proteins for vesicle-membrane fusion at the Golgi-endosomal interface, for the endoplasmic reticulum unfolded protein response and for a myelin structural component.

Download full-text

Full-text

Available from: Irene Litvan, Jul 30, 2015
2 Followers
 · 
284 Views
  • Source
    • "Additional support for a role for vesicular sorting and trafficking of membrane-associated proteins in PD biology has been provided by pathogenic mutations in LRRK2 [9], VPS35 resulting in autosomal dominant PD [10], and DNAJC6 mutations causing juvenile recessive PD [11]. Hoglinger et al., 2011 found three single nucleotide polymorphisms (SNPs) that were significantly associated with PSP risk at STX6, EIF2AK3 and MOBP. STX6 rs1411478 has an odds ratio of 0.73 (range from 0.65 to 0.81) and a p-value of 1.8 Â 10 À9 . "
    [Show abstract] [Hide abstract]
    ABSTRACT: A variant in Syntaxin 6 (a soluble N-ethylmaleimide-sensitive factor attachment protein receptor STX6) (rs1411478) has been shown to be associated with progressive supranuclear palsy (PSP). Although Parkinson's disease (PD) and PSP are distinct neurodegenerative diseases, they share some clinical and genetic features. In this study, we evaluated STX6 genetic variability in PD susceptibility in ethnically matched case-control series from Canada, Norway, Taiwan and Tunisia and we evaluated the presence of pathogenic mutations within families. No pathogenic mutations were found in STX6. Similarly, statistical analysis of rs1411478 failed to identify differences in genotype or allelic frequencies between cases and controls. Our results do not support a role for STX6 in PD.
    Parkinsonism & Related Disorders 02/2013; 19(5). DOI:10.1016/j.parkreldis.2013.01.019 · 4.13 Impact Factor
  • Source
    • "Although linkage analysis along with candidate gene screening was traditionally the preferred method for gene discovery in inherited MDs (Paisan-Ruiz et al., 2004, 2005), these are not appropriate for families with largely reduced penetrance or reduced number of affected individuals. And even though there has been considerable success in identifying genetic risk factors for PD and PSP through the application of genome-wide association studies (GWAS; Simon-Sanchez et al., 2009; Hamza et al., 2010; Hoglinger et al., 2011), a detailed mapping through targeted resequencing (TR) is still required to further identify both high-risk alleles and haplotypes (Tucci et al., 2010; Freedman et al., 2011). By contrast, next-generation sequencing (NGS) technologies, such as exome sequencing (ES) and whole-genome sequencing (WGS), enable "
    [Show abstract] [Hide abstract]
    ABSTRACT: New advances in genomic technology are being introduced at a greater speed and are revolutionizing the field of genetics for both complex and Mendelian diseases. For instance, during the past few years, genome-wide association studies (GWAS) have identified a large number of significant associations between genomic loci and movement disorders such as Parkinson's disease and progressive supranuclear palsy. GWAS are carried out through the use of high-throughput SNP genotyping arrays, which are also used to perform linkage analyses in families previously considered statistically underpowered for genetic analyses. In inherited movement disorders, using this latter technology, it has repeatedly been shown that mutations in a single gene can lead to different phenotypes, while the same clinical entity can be caused by mutations in different genes. This is being highlighted with the use of next-generation sequencing technologies and leads to the search for genes or genetic modifiers that contribute to the phenotypic expression of movement disorders. Establishing an accurate genome-epigenome-phenotype relationship is becoming a major challenge in the post-genomic research that should be facilitated through the implementation of both functional and cellular analyses.
    Frontiers in Genetics 05/2012; 3:75. DOI:10.3389/fgene.2012.00075
  • Source
    • "Additional associations included a series of SNPs on chromosome 17. Previous studies have noted an effect of chromo- some17 SNPs on expression of the MAPT gene that is associated with risk of PD and PSP (2011; Hoglinger et al., 2011 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Genome-wide association studies have nominated many genetic variants for common human traits, including diseases, but in many cases the underlying biological reason for a trait association is unknown. Subsets of genetic polymorphisms show a statistical association with transcript expression levels, and have therefore been nominated as expression quantitative trait loci (eQTL). However, many tissue and cell types have specific gene expression patterns and so it is not clear how frequently eQTLs found in one tissue type will be replicated in others. In the present study we used two appropriately powered sample series to examine the genetic control of gene expression in blood and brain. We find that while many eQTLs associated with human traits are shared between these two tissues, there are also examples where blood and brain differ, either by restricted gene expression patterns in one tissue or because of differences in how genetic variants are associated with transcript levels. These observations suggest that design of eQTL mapping experiments should consider tissue of interest for the disease or other traits studied.
    Neurobiology of Disease 03/2012; 47(1):20-8. DOI:10.1016/j.nbd.2012.03.020 · 5.20 Impact Factor
Show more